Next Gen Diagnostics (NGD) is pioneering advancements in infection control and clinical microbiology through its innovative approach to whole genome sequencing (WGS). The company has developed a fully automated bioinformatics system that integrates seamlessly with a microfluidic sample preparation and sequencing pipeline. This technology allows hospitals to conduct high-volume WGS sample preparation and sequencing efficiently and cost-effectively. The results are made available on the NGD Dashboard the following morning, providing infection control teams with immediate access to analyzed data. This rapid turnaround enables timely validation and intervention in potential infection transmission, significantly enhancing outbreak prevention efforts.

The microfluidic sample preparation technology employed by NGD is designed to handle large volumes of samples daily while ensuring high-quality results and traceability. This proprietary system automates critical processes such as extraction, library preparation, and barcoding, all at an unprecedentedly low cost. Additionally, the NGD Dashboard offers features like antibiogram prediction and resistome enumeration, which provide insights into resistance genes and mutations present in each sample. By streamlining these processes, NGD not only reduces operational costs but also ensures compliance with best practices in healthcare-associated infection (HAI) management.

United Kingdom

Low-cost, rapid whole genome sequencing is the future of infection control and clinical microbiology. Next Gen Diagnostics offers the low cost, high throughput, and automated sequencing and bioinformatics for a range of application, including tracking the transmission of disease in hospitals and pathogen surveillance for public health labs.


Next Gen Diagnostics

Company Details